Applications of 4-Chloro-5-(Chlorosulfonyl)-2-Fluorobenzoic Acid in Industrial Manufacturing

Our production-grade 4-Chloro-5-(Chlorosulfonyl)-2-Fluorobenzoic Acid integrates into strict, high-value intermediate synthesis across pharmaceutical and agrochemical manufacturing, meeting the evolving regulatory and process demands of the sector. Below, we detail authentic, grounded downstream scenarios proven in industrial-scale operations.

1. Pharmaceutical Intermediate for Anti-Inflammatory Drug Synthesis

Several anti-inflammatory APIs employ this compound as an advanced building block, owing to its dual halogen and sulfonyl functionality, which imparts selectivity in targeted coupling reactions. Our manufacturing partners integrate it readily for constructing key benzoic acid core structures in NSAID and related therapeutics, operational under cGMP and maintaining strict impurity control during amidation or carboxylation steps, where by-products must meet pharmacopeial thresholds.

Industry compliance standards

• ICH Q7 Good Manufacturing Practices
• USP-NF for residual solvent and impurity profile
• EU Pharmacopoeia 2.4.24 and 5.1.4 for elemental impurities
• FDA 21 CFR Part 210/211 process validation

Typical usage ratio

• 0.5–2.3 molar equivalents per API batch, adjusted based on molecular route and desired selectivity in multi-step synthesis; process chemists determine the precise stoichiometry after route scouting.

Downstream process integration

• Charge during the main substrate coupling stage or late-stage sulfonation, often under nitrogen atmosphere with controlled temperature ramp; added post-purification to avoid trace halide contamination in final crystallization step.

Final product types

• Anti-inflammatory API intermediates
• Generic drug substances (NSAIDs with benzoic acid scaffold)
• Specialty analgesic excipients
• Stabilized injectable pre-formulations

2. Agrochemical Active Ingredient Intermediate (Herbicide Synthesis)

Major agrichemical producers rely on the selectivity of this compound during the formation of fluorinated benzoic backbones within herbicide active ingredient synthesis. The compound’s chlorosulfonyl group enables precision sulfonation for downstream ring closures, crucial for maintaining consistent weed suppression profiles while adhering to increasing regulatory scrutiny regarding process residues and purity for field application registration.

Industry compliance standards

• FAO/WHO JMPR technical specifications for pesticide actives
• REACH Annex XVII restricted substances for field residual limits
• OECD Good Laboratory Practice (GLP) for residue trials
• China GB 2763 MRLs for agrochemical residues

Typical usage ratio

• 8–14% w/w in core intermediate synthesis; formulation chemists optimize input based on target active yield, maintaining compliance with reaction by-product guidelines.

Downstream process integration

• Key charge in regioselective sulfonation or chlorination during preparation of herbicide pre-mixes; compound enters at intermediate coupling step and must clear HPLC analysis before final formulation blending.

Final product types

• Herbicide active intermediates
• Selective pre-emergent herbicides
• Cereal and maize crop protectant actives
• Formulated wettable granule herbicide products

3. Synthesis of Fluorinated Specialty Polymers for Electronic Components

Electronics material manufacturers employ the compound for producing high-purity monomers that impart chemical resistance and dielectric properties in specialty fluoropolymers, notably for PCB laminates and sensor encapsulation layers. The unique substitution pattern allows downstream polymerization with fine control over crosslink density, while QC teams monitor for ionic contamination to comply with advanced electronics reliability standards.

Industry compliance standards

• IPC-4101D for base materials for printed boards
• IEC 61249-2 for plastics in electrical applications
• RoHS Directive (EU) 2015/863 for halogen and sulfonate content
• UL 94 for polymer flame retardancy

Typical usage ratio

• 0.3–1.5 mol percent as comonomer or chain end-capper, depending on the target molecular weight and dielectric specification; ratio fine-tuned through pilot polymerization trials.

Downstream process integration

• Introduced as a functionalized monomer during initial oligomer formation or as a post-polymerization modifier to adjust electrophilicity prior to compounding; strictly managed under dry/inert processing conditions to prevent hydrolysis.

Final product types

• High-frequency PCB base films
• Sensor encapsulation resins
• Low-dielectric circuit laminates
• Fluorinated microelectronic adhesives

4. Synthesis of Advanced Dye Intermediates for Industrial Textiles

Textile chemical producers utilize this benzoic derivative as a precision coupling agent for the synthesis of high-fastness dyes, especially where specific halogenated or sulfonated aromatic motifs are necessary to optimize chroma and wash resistance. The compound enters controlled azo or sulfone coupling, with standardised batch analytics to ensure absence of regulated impurities, crucial for greige or finished textiles exported to regions with strict eco-labeling policies.

Industry compliance standards

• OEKO-TEX Standard 100 for chemical safety
• ZDHC MRSL V3.1 list for dye substance approval
• EU REACH Regulation (EC) No 1907/2006 for azo/hazardous amines
• ISO 105-C06 for colorfastness requirements

Typical usage ratio

• 12–22% of dye intermediate feed batch, with adjustment per shade depth and molecular compatibility testing; textile chemists perform iterative color-matching QC prior to scale-up.

Downstream process integration

• Used during main aromatic coupling or sulfone bridge installation in intermediate dye synthesis; product passes through multiple recrystallization and HPLC purity stages before being submitted for pilot textile dyeing trials.

Final product types

• Reactive dye intermediates
• Disperse textile dyes
• Polyester and nylon dyeings
• Industrial wash-fast textile colorants

5. Pharmaceutical Intermediate for Oncology Drug Development

This compound serves as a halogenated building block in the synthesis of critical kinase inhibitor scaffolds for targeted oncology therapies, due to its substitution pattern which permits high selectivity in palladium-catalyzed cross-coupling reactions. QC and chemist teams refine stoichiometry to control potential genotoxic impurities, dedicating isolation lines for trace analysis to satisfy stringent oncology regulatory filings.

Industry compliance standards

• ICH M7(R1) guideline for mutagenic impurities control
• FDA Guidance for Industry: ANDA submissions, impurity limits for oncology APIs
• WHO TRS 970 cGMP for active pharmaceutical ingredient manufacturing
• Japanese Pharmacopoeia General Notices

Typical usage ratio

• 0.7–1.0 molar proportion per cross-coupling stage, set during process validation based on catalyst system and scale-up impurity profiles.

Downstream process integration

• Added during core ring assembly or halide-sulfonyl exchange; material held under segregated handling with multi-stage impurity clearance prior to inclusion in lead-optimization synthesis campaigns.

Final product types

• Kinase inhibitor intermediates
• Precision-targeted small molecule oncology APIs
• Preclinical research compounds for investigational therapies
• Chemically modified peptide conjugates

6. Intermediate for Synthesis of Advanced Imaging Agent Precursors

Medical imaging contrast agent producers use this compound as a precursor for incorporating specific fluorine and sulfonyl functionality, required to modulate hydrophilicity and binding affinity of gadolinium chelates and other diagnostic agents. The manufacturing lines enforce rigorous tracking for radiochemical purity and ensure contaminant levels observe radiopharma grade thresholds set for both EU and US approvals.

Industry compliance standards

• USP 823 for PET radiopharmaceuticals
• European Pharmacopoeia 01/2018:1150 for injectable contrast agents
• FDA 21 CFR 212 for radiopharmaceuticals cGMP
• ISO 13485:2016 for diagnostic agent manufacturing

Typical usage ratio

• 1–5% of total precursor input, varying by binding affinity and chelate density required in imaging agent formulation; process engineers tune this during R&D pilot validation.

Downstream process integration

• Dosed during late-stage fluorination or sulfonyl functionalization, ahead of chelating agent coupling; each lot undergoes radiochemical purity verification with gamma spectrometry and HPLC analysis before batch release.

Final product types

• Gadolinium-based MRI contrast intermediates
• Fluorine-18 PET scan agent precursors
• Diagnostic agent synthesis blocks
• Radio-opaque injectable component bases